Godzilla Vs. The Life Sciences Supply Chain

Author(s): Dan Mathews

As fans of classic Japanese movies may remember, the pharmaceutical industry has experience with Godzilla. In the 1962 movie King Kong vs Godzilla, Mr Tako, director of Pacific Pharmaceuticals, helps Japan defend herself against the mutant dinosaur by recruiting King Kong to fight him. Unfortunately for the life sciences sector, the predicted 2026 “Godzilla” El Niño event may present an even bigger threat than the monster did — and may need a smarter approach than Mr Tako’s giant gorilla-based strategy.

The risk is real: Meteorologists project an 82% chance that the periodic oceanic heatwave will emerge by mid-2026 and persist into 2027 and may be the most high-impact El Niño event in history. In its wake, 2027 could rank among the hottest years on record — just as 2024 set that record after the last El Niño, augmenting the intensity of floods, typhoons and other extreme weather phenomena. The potential problems looming particularly large for the life sciences sector include major weather disruptions being likely to disproportionately affect key manufacturing geographies in the Asia-Pacific region, including China and India, where the industry’s raw materials and active pharmaceutical ingredients (APIs) sources are concentrated.